Project Grant R01HL188233
Award Date 8/15/26
Completion Date 5/31/30
Dollars Obligated $804K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
- The National Heart, Lung, and Blood Institute, under the Department of Health and Human Services National Institutes of Health, awarded The Washington University $768,128 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to mechanistically evaluate the role of oscillatory shear stress in deep vein thrombosis prevention. The recipient will conduct in vitro, in vivo, and human model studies to determine whether restoration of oscillatory shear stress in veins...
- The National Institute of Neurological Disorders and Stroke awarded Washington University $231,264 on April 8, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to identify and validate cerebroprotective drug targets in humans with acute ischemic stroke caused by large vessel occlusion. The research collects paired periprocedural arterial blood samples during endovascular thrombectomy procedures at Barnes-Jewish Hospital/Washington...
- The National Heart, Lung, and Blood Institute awarded The Washington University $764,681 under the Cardiovascular Diseases Research program (CFDA 93.837) on May 1, 2026, to conduct research into a multipotent fibroblast population and platelet-derived growth factor receptor beta–dependent immuno-fibrotic responses in heart failure. The research addresses cardiac fibrosis and left ventricular dysfunction in heart failure by investigating a novel population of stem cell antigen-1–expressing,...
- The National Heart, Lung, and Blood Institute awarded The Washington University $550,896 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop targeted nanotherapy for acute myocardial infarction. The project, led by Principal Investigator Jianjun Guan, will encapsulate an engineered secretome derived from naive M0 macrophages into nanoparticles for intravenous administration to simultaneously address three critical post-infarction pathologies:...
- The National Heart Lung and Blood Institute awarded the Regents of the University of Michigan $567,166 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop tunable multi-thrombolytic nanoformulations for treating ischemic stroke with minimal hemorrhagic risk. The research addresses limitations of current thrombolytic therapy—tissue plasminogen activator (tPA) carries serious intracranial hemorrhage complications, while plasmin, a more effective...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $1,081,420 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct basic and translational research on platelet activation pathways and disorders of platelet count and function. The recipient will investigate cellular signaling pathways—particularly G proteins and integrin receptors—that control platelet adhesion and plug formation in hemostasis and...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $902,000 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop an abbreviated cardiovascular magnetic resonance imaging solution for time-efficient, cost-effective etiology diagnosis of acute ischemic stroke. The project develops a 10-minute abbreviated cardiovascular MRI protocol designed to identify the underlying cause of acute ischemic...
- The National Heart, Lung, and Blood Institute awarded The Washington University $1.902 million on June 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define and correct immune-epithelial pathways underlying chronic muco-obstructive lung disease triggered by viral infection, allergen, smoke, or pollution exposure. The research identifies and characterizes a distinct subset of basal epithelial stem cells (basal-ESCs) that drive muco-obstructive disease phenotypes...
- The National Heart, Lung, and Blood Institute awarded the University of Illinois $1.6 million under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, to investigate GA12-dependent mechanisms of basal and regulated endothelial cell von Willebrand factor (VWF) secretion. This is a Project Grant (R01HL186410). The research addresses microvascular thrombotic occlusions in inflammatory conditions such as sepsis and sickle cell disease, where elevated VWF plasma levels...
- The National Heart, Lung, and Blood Institute awarded The Washington University $233,250 under the Cardiovascular Diseases Research program (CFDA 93.837) on June 15, 2026, to investigate the mechanisms by which mycophenolic acid (MPA) induces neutropenia in lung transplant recipients. The research examines how MPA influences neutrophil development, survival, and effector function, with a hypothesis that MPA disrupts metabolic pathways—particularly glycolysis—and alters gene expression during...